KDIGO clinical practice guideline on the evaluation and care of living kidney donors
KL Lentine, BL Kasiske, AS Levey, PL Adams… - …, 2017 - journals.lww.com
Abstract The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice
Guideline on the Evaluation and Care of Living Kidney Donors is intended to assist medical …
Guideline on the Evaluation and Care of Living Kidney Donors is intended to assist medical …
Infectious complications and malignancies arising after liver transplantation
DW Idossa, DA Simonetto - Anesthesiology Clinics, 2017 - anesthesiology.theclinics.com
Since the first liver transplant was performed in 1963, great advancements have been made
in the field of hepatic transplantation. Surgical techniques have been revised and improved; …
in the field of hepatic transplantation. Surgical techniques have been revised and improved; …
Cytomegalovirus in liver transplant recipients
D Herman, H Han - Current Opinion in Organ Transplantation, 2017 - journals.lww.com
Given these findings, continuing efforts are underway to determine whether further therapy,
vaccination, or alternative management strategies may improve outcomes in solid-organ …
vaccination, or alternative management strategies may improve outcomes in solid-organ …
Pharmacokinetics and safety of letermovir, a novel anti‐human cytomegalovirus drug, in patients with renal impairment
D Kropeit, J Scheuenpflug, K Erb‐Zohar… - British Journal of …, 2017 - Wiley Online Library
Aims Human cytomegalovirus remains a significant issue for immunocompromised patients
and existing viral polymerase targeting therapies are associated with significant toxicity …
and existing viral polymerase targeting therapies are associated with significant toxicity …
Pharmacokinetics and safety of the anti‐human cytomegalovirus drug letermovir in subjects with hepatic impairment
D Kropeit, D McCormick, K Erb‐Zohar… - British Journal of …, 2017 - Wiley Online Library
Aims Human cytomegalovirus constitutes a prevalent and serious threat to
immunocompromised individuals and requires new treatments. Letermovir is a novel viral …
immunocompromised individuals and requires new treatments. Letermovir is a novel viral …
Brincidofovir use after foscarnet crystal nephropathy in a kidney transplant recipient with multiresistant cytomegalovirus infection
R Vial, C Zandotti, S Alain, A Decourt… - Case reports in …, 2017 - Wiley Online Library
Background. Cytomegalovirus (CMV) antiviral drug resistance constitutes an increasing
challenge in transplantation. Foscarnet is usually proposed when resistance for ganciclovir …
challenge in transplantation. Foscarnet is usually proposed when resistance for ganciclovir …
Impact of age and cytomegalovirus on CD8+ T-cell compartment remodeling after solid organ transplantation: a one-year follow-up study
S Cantisán, A Páez-Vega, F Santos… - Experimental …, 2017 - Elsevier
Cytomegalovirus (CMV), a member of the β-herpesvirus family, is a major complicating
infection in transplant patients. CMV latency has a long-term impact on CD8+ T-cell …
infection in transplant patients. CMV latency has a long-term impact on CD8+ T-cell …
Enzyme-linked immunospot assay as a complementary method to assess and monitor cytomegalovirus infection in kidney transplant recipients on pre-emptive …
Background Cytomegalovirus (CMV) disease represents a major cause of post-
transplantation morbidity and mortality. To estimate the risk of infection and monitor …
transplantation morbidity and mortality. To estimate the risk of infection and monitor …
细胞核染色法检测人免疫球蛋白类制品巨细胞病毒中和抗体效价
王敏力， 秦婷婷， 刘波， 杨春， 刘兰军， 侯继锋 - 中国生物制品学杂志, 2017 - cqvip.com
目的检测静注免疫球蛋白(intravenous immunoglobulin, IVIG)(p H 4) 及巨细胞病毒(
cytomegalovirus, CMV) 免疫球蛋白(IG) 中的CMV 中和抗体效价. 方法采用基于微量细胞病变的 …
cytomegalovirus, CMV) 免疫球蛋白(IG) 中的CMV 中和抗体效价. 方法采用基于微量细胞病变的 …
器官移植后巨细胞病毒耐药的处理
康一生， 于立新 - 器官移植, 2017 - cqvip.com
巨细胞病毒(CMV) 感染是器官移植术后常见的并发症, 其耐药发生亦非罕见,
且易导致临床预后不良. CMV 耐药的危险因素来源于宿主, 病毒以及抗病毒药物等各个方面 …
且易导致临床预后不良. CMV 耐药的危险因素来源于宿主, 病毒以及抗病毒药物等各个方面 …